Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: Can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy?

被引:94
作者
Ankola, D. D.
Viswanad, B.
Bhardwa, V.
Ramarao, P.
Kumar, M. N. V. Ravi [1 ]
机构
[1] NIPER, Dept Pharmaceut, SAS Nagar 160062, Punjab, India
[2] NIPER, Ctr Pharmaceut Nanotechnol, SAS Nagar, Punjab, India
[3] NIPER, Dept Pharmacol & Toxicol, SAS Nagar, Punjab, India
关键词
antioxidants; Bioavailability; biodegradable; free radical; hypertension; nanoparticles; oral delivery;
D O I
10.1016/j.ejpb.2007.03.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Coenzyme Q10 (CoQ10) is an antioxidant with well-established pharmacological activities against several chronic diseases; however, it is marketed only as a nutritional supplement without any claims of its therapeutic activity and one of the reasons for this could be the poor oral bioavailability rendering difficulties in administering this molecule to achieve therapeutic concentrations. Therefore, the present investigation was aimed at improving the oral bioavailability of CoQ10 by delivering it as nanoparticulate formulation. Biodegradable nanoparticulate formulations based on poly(lactide-co-gylcolide) (PLGA) were prepared by emulsion technique using quaternary ammonium salt didodecyldimethylammonium bromide (DMAB) as a stabilizer. The effect of initial CoQ10 loading on entrapment efficiency and the particle size was studied using 5-75% initial load resulting in good entrapment efficiency (61-83%) without any appreciable increase in the particle size for 5-30% loading (107-110 nm). However, 50% and 75% led to increase in particle size with no appreciable changes in entrapment efficiency. The intestinal uptake of CoQ10 as a suspension in carboxymethylcellulose (CIVIC), a commercial formulation and the developed nanoparticulate formulation was studied in male Sprague-Dawley (SD) rats and found to be 45%, 75% and 79%, respectively, suggesting that solubility and permeability related problems of CoQ10 were overcome by nanoparticulate formulation. Furthermore, the developed nanoparticulate formulation was evaluated for its therapeutic potential in renal hypertensive animals (Goldblatt 2K1C model), demonstrating improved efficacy at a 60% lowered dose as compared to CoQ10 suspension and superior efficacy than the commercial formulation at an equal dose. Together, these results indicate the potential of nanotechnology in improving the therapeutic value of molecules like CoQ10, facilitating its usage as first line therapeutic agent thus revolutionizing its role in current medical therapy. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:361 / 369
页数:9
相关论文
共 30 条
[1]   DISTRIBUTION AND REDOX STATE OF UBIQUINONES IN RAT AND HUMAN TISSUES [J].
ABERG, F ;
APPELKVIST, EL ;
DALLNER, G ;
ERNSTER, L .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1992, 295 (02) :230-234
[2]   AT1 receptors and L-type calcium channels:: functional coupling in supersensitivity to angiotensin II in diabetic rats [J].
Arun, KHS ;
Kaul, CL ;
Ramarao, P .
CARDIOVASCULAR RESEARCH, 2005, 65 (02) :374-386
[3]   Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration [J].
Bala, I ;
Bhardwaj, V ;
Hariharan, S ;
Kharade, SV ;
Roy, N ;
Kumar, MNVR .
JOURNAL OF DRUG TARGETING, 2006, 14 (01) :27-34
[4]   Design of biodegradable nanoparticles: a novel approach to encapsulating poorly soluble phytochemical ellagic acid [J].
Bala, I ;
Bhardwaj, V ;
Hariharan, S ;
Sitterberg, J ;
Bakowsky, U ;
Kumar, MNVR .
NANOTECHNOLOGY, 2005, 16 (12) :2819-2822
[5]   PLGA nanoparticles in drug delivery: The state of the art [J].
Bala, I ;
Hariharan, S ;
Kumar, MNVR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (05) :387-422
[6]   Pharmaceutical Aspects of Polymeric Nanoparticles for Oral Drug Delivery [J].
Bhardwaj, V. ;
Hariharan, S. ;
Bala, I. ;
Lamprecht, A. ;
Kumar, N. ;
Panchagnula, R. ;
Kumar, M. N. V. Ravi .
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2005, 1 (03) :235-258
[7]  
Brown CK, 2004, Pharm Tech, V28, P56, DOI [10.14227/DT120405P6, DOI 10.14227/DT120405P6]
[8]   MODIFIED SILVER CLIP USED IN INDUCTION OF RENAL-HYPERTENSION IN RAT [J].
BURNS, J ;
ROBBINS, BG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1972, 24 (01) :86-&
[9]   Oral particulate delivery: status and future trends [J].
Chen, HM ;
Langer, R .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 34 (2-3) :339-350
[10]  
Chopra RK, 1998, INT J VITAM NUTR RES, V68, P109